Find Hematology Drugs in Phase III Clinical Development in UNITED STATES

Lead Product(s): Danicopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

Deal Size: $930.0 million Upfront Cash: $930.0 million

Deal Type: Acquisition January 28, 2020

Details:

Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

Lead Product(s): Avatrombopag

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Lead Product(s): APL 2

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

In a head-to-head phase 3 trial after 16 weeks, hemoglobin levels in the pegcetacoplan arm had increased by 3.8 g/dL over the Soliris group, resulting in the trial hitting its primary endpoint.